Pro-Qura

Pro-Qura, Inc. was a Seattle-based healthcare company specializing in the management and quality assurance of brachytherapy treatments for prostate cancer. Founded in 2002, the company provided specialized dosimetry and treatment planning services to ensure the precise delivery of radioactive seeds to cancerous tissue while minimizing damage to surrounding organs. Pro-Qura is well-known in the medical community for its multi-institutional database of prostate brachytherapy dosimetry, which has been used in numerous clinical studies to standardize and improve treatment outcomes. The company's leadership, including former CEO Lori Woods, played a significant role in the commercialization of Cesium-131 isotopes for cancer therapy. Although the company is no longer independently active, its legacy continues through the widely cited Pro-Qura database and the subsequent work of its executives in the medical technology sector.